Literature DB >> 28552326

Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.

Christian Grommes1, Anas Younes2.   

Abstract

In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was associated with significant toxicity, including pulmonary and cerebral aspergillosis infections.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28552326      PMCID： PMC5572136          DOI： 10.1016/j.ccell.2017.05.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.

Authors:  Sophie Camilleri-Broët; Emmanuelle Crinière; Philippe Broët; Vincent Delwail; Karima Mokhtari; Anne Moreau; Michèle Kujas; Martine Raphaël; Wafae Iraqi; Catherine Sautès-Fridman; Philippe Colombat; Khê Hoang-Xuan; Antoine Martin
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

3.  Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

Authors:  Kristoph Jahnke; Eckhard Thiel; Peter Martus; Ulrich Herrlinger; Michael Weller; Lars Fischer; Agnieszka Korfel
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

4.  Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Authors:  Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Valter Torri; Christopher P Fox; Paul La Rosée; Elisabeth Schorb; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Angela Ferrari; Kim M Linton; Roberta Rudà; Mascha Binder; Tobias Pukrop; Monica Balzarotti; Alberto Fabbri; Peter Johnson; Jette Sønderskov Gørløv; Georg Hess; Jens Panse; Francesco Pisani; Alessandra Tucci; Stephan Stilgenbauer; Bernd Hertenstein; Ulrich Keller; Stefan W Krause; Alessandro Levis; Hans J Schmoll; Franco Cavalli; Jürgen Finke; Michele Reni; Emanuele Zucca; Gerald Illerhaus
Journal:  Lancet Haematol       Date:  2016-04-06       Impact factor: 18.959

5.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Authors:  Andrés J M Ferreri; Michele Reni; Marco Foppoli; Maurizio Martelli; Gerasimus A Pangalis; Maurizio Frezzato; Maria Giuseppina Cabras; Alberto Fabbri; Gaetano Corazzelli; Fiorella Ilariucci; Giuseppe Rossi; Riccardo Soffietti; Caterina Stelitano; Daniele Vallisa; Francesco Zaja; Lucía Zoppegno; Gian Marco Aondio; Giuseppe Avvisati; Monica Balzarotti; Alba A Brandes; José Fajardo; Henry Gomez; Attilio Guarini; Graziella Pinotti; Luigi Rigacci; Catrina Uhlmann; Piero Picozzi; Paolo Vezzulli; Maurilio Ponzoni; Emanuele Zucca; Federico Caligaris-Cappio; Franco Cavalli
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

6.  Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

Authors:  Carole Soussain; Khê Hoang-Xuan; Luc Taillandier; Emmanuelle Fourme; Sylvain Choquet; Francis Witz; Olivier Casasnovas; Brigitte Dupriez; Bertrand Souleau; Anne-Laure Taksin; Christian Gisselbrecht; Arnaud Jaccard; Antonio Omuro; Marc Sanson; Maud Janvier; Brigitte Kolb; Jean-Marc Zini; Véronique Leblond
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

7.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

Review 8.  Second-line treatment for primary central nervous system lymphoma.

Authors:  M Reni; A J Ferreri; E Villa
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640
  8 in total
  14 in total

1.  First-line ibrutinib for Bing-Neel syndrome.

Authors:  Aaron Tallant; Daniel Selig; Sam O Wanko; Joseph Roswarski
Journal:  BMJ Case Rep       Date:  2018-10-02

2.  Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia.

Authors:  Silvia Martinelli; Rossana Maffei; Stefania Fiorcari; Chiara Quadrelli; Patrizia Zucchini; Stefania Benatti; Leonardo Potenza; Mario Luppi; Roberto Marasca
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

3.  Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Authors:  Han W Tun; Patrick B Johnston; Lisa M DeAngelis; Pamela J Atherton; Levi D Pederson; Patricia A Koenig; Craig B Reeder; Antonio M Padula Omuro; David Schiff; Brian O'Neill; Jose Pulido; Kurt A Jaeckle; Christian Grommes; Thomas E Witzig
Journal:  Blood       Date:  2018-09-27       Impact factor: 22.113

Review 4.  Biology of CNS lymphoma and the potential of novel agents.

Authors:  James L Rubenstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma.

Authors:  Justin J Kuhlman; Muhamad Alhaj Moustafa; Liuyan Jiang; Jing Wang; Vivek Gupta; Han W Tun
Journal:  Blood Lymphat Cancer       Date:  2022-04-14

Review 6.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

Review 7.  Prophylaxis of mould infections.

Authors:  E Moreno-García; M Chumbita; P Puerta-Alcalde; C Cardozo; C García-Vidal
Journal:  Rev Esp Quimioter       Date:  2019-09       Impact factor: 1.553

8.  Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.

Authors:  Damien Blez; Marion Blaize; Carole Soussain; Alexandre Boissonnas; Aïda Meghraoui-Kheddar; Natacha Menezes; Anaïs Portalier; Christophe Combadière; Véronique Leblond; David Ghez; Arnaud Fekkar
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

9.  Invasive Aspergillosis in Patients Treated With Ibrutinib.

Authors:  Moritz Fürstenau; Florian Simon; Oliver A Cornely; Tillman Hicketier; Barbara Eichhorst; Michael Hallek; Sibylle C Mellinghoff
Journal:  Hemasphere       Date:  2020-02-13

10.  Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.

Authors:  Jörg Janne Vehreschild; Philipp Koehler; Frédéric Lamoth; Juergen Prattes; Christina Rieger; Bart J A Rijnders; Daniel Teschner
Journal:  Med Mycol       Date:  2021-01-04       Impact factor: 4.076
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.